Scholarlink

<p>Fluctuations often complicate the course of Parkinson’s disease (PD). The third-generation catechol-<i>O</i>-methyltransferase inhibitor, opicapone, is safe and effective in patients with PD motor fluctuations, whether long-standing or earlier onset. Real-world data are needed to identify the most appropriate candidates for initiating and sustaining therapy with opicapone. To evaluate the long-term outcomes and identify predictors for safer and prolonged use of opicapone. This real-world, longitudinal, multicenter, retrospective study collected data on the demographics, medical history, motor subtype, motor severity, cognitive and psychiatric disorders at baseline when opicapone was introduced as add-on therapy and at the last follow-up. Discontinuation rates and main causes were recorded. Clinical features of patients who continued/discontinued were compared to identify predictors for drug discontinuation and define successful long-term outcomes. Of the 178 enrolled patients, 85% (35% of them female) continued opicapone for a mean of 30.2 ± 19.64&#xa0;months. The remaining 15% (13.4% female) discontinued opicapone within 8.9 ± 11.30&#xa0;months due to disabling dyskinesia, hypotension, gastrointestinal disorders, or psychiatric disturbances. Continuers were younger at baseline than those who discontinued, but clinical-demographic features did not predict continuing opicapone therapy. Continuers had significantly lower Hoehn and Yahr scale scores and fewer night-time OFF periods compared with discontinuers, whereas levodopa equivalent daily dose and burden of motor and neuropsychiatric complications were similar. Continued opicapone therapy was associated with less motor impairment and reduced night-time OFF. Safety and long-term tolerability were higher in younger patients with a tendency to milder motor severity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Opicapone in Parkinson’s disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月31日

查看全文
  • Clelia Pellicano,
  • Daniele Belvisi,
  • Roberta Bovenzi,
  • Matteo Costanzo,
  • Maria I. De Bartolo,
  • Francesca Sommaruga,
  • Jessica Blandino,
  • Nicola Modugno,
  • Fabrizio Piras,
  • Mariangela Pierantozzi,
  • Alessandro Stefani,
  • Giovanni Fabbrini,
  • Tommaso Schirinzi

摘要

Fluctuations often complicate the course of Parkinson’s disease (PD). The third-generation catechol-O-methyltransferase inhibitor, opicapone, is safe and effective in patients with PD motor fluctuations, whether long-standing or earlier onset. Real-world data are needed to identify the most appropriate candidates for initiating and sustaining therapy with opicapone. To evaluate the long-term outcomes and identify predictors for safer and prolonged use of opicapone. This real-world, longitudinal, multicenter, retrospective study collected data on the demographics, medical history, motor subtype, motor severity, cognitive and psychiatric disorders at baseline when opicapone was introduced as add-on therapy and at the last follow-up. Discontinuation rates and main causes were recorded. Clinical features of patients who continued/discontinued were compared to identify predictors for drug discontinuation and define successful long-term outcomes. Of the 178 enrolled patients, 85% (35% of them female) continued opicapone for a mean of 30.2 ± 19.64 months. The remaining 15% (13.4% female) discontinued opicapone within 8.9 ± 11.30 months due to disabling dyskinesia, hypotension, gastrointestinal disorders, or psychiatric disturbances. Continuers were younger at baseline than those who discontinued, but clinical-demographic features did not predict continuing opicapone therapy. Continuers had significantly lower Hoehn and Yahr scale scores and fewer night-time OFF periods compared with discontinuers, whereas levodopa equivalent daily dose and burden of motor and neuropsychiatric complications were similar. Continued opicapone therapy was associated with less motor impairment and reduced night-time OFF. Safety and long-term tolerability were higher in younger patients with a tendency to milder motor severity.